FarmaKology Newsletter - Issue #15
BenevolentAI is the global leader in the development and application of artificial intelligence (“AI”) for scientific innovation. We aim to accelerate the journey from inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world’s 8,000 untreated diseases.
Faron Pharmaceuticals has reported new findings from the open-label Phase I/II MATINS clinical trial of its cancer immunotherapy Clevegen for the treatment of certain metastatic or inoperable solid tumours.Clevegen is an anti-Clever-1 antibody that can switch immune suppression to immune activation, with potential for application in oncology, infectious disease, and vaccine development.
The Chief Executive Officer of Avicenna Pharmacy has confirmed that Juno Health has bought the independent pharmacy support group. Salim Jetha told Pharmacy Business on Friday that the acquisition is expected to benefit Avicenna members because Juno Health promises to continue “existing services with further investment to enhance these”.
A digital communication system, which highlights patients who need extra support with antipsychotics and antidepressants, has been developed by Cheshire and Wirral Partnership NHS Trust and shown resounding success in pilot.
GlaxoSmithKline laid out $5.1 billion last year for Tesaro and its key PARP inhibitor, Zejula, and with some new first-line ovarian cancer data, it has another chance to prove the deal was worth it.